FAPI in Rectal Cancer TNT

68Ga FAPI in Total Neoadjuvant Therapy of Rectal Cancer

The goal of the trial is to observe the changes of 68Ga FAPI signal before and after total neoadjuvant therapy for rectal cancers, and the correlation between the image parameters, immune checkpoints expression as well as the patient outcome. The trial will recruit patients with biopsy-confirmed rectal cancer aged 18 years old or older, with WHO/ECOG Performance Status 0-1, and eligible for total neoadjuvant therapy at the clinicians' discretion. After signing the informed consent, the participants will undergo a standard staging work-up if not already done, including colonoscopy and cross-sectional images such as CT, MR, and FDG-PET. Kidney function (by serum creatinine) and liver function (by serum alanine aminotransferase) will also be assessed. Only patients with stage II-III rectal cancer will be recruited.

If patients meet the inclusion and exclusion criteria, they will undergo the first 68Ga-FAPI PET within 30 days before the beginning of total neoadjuvant therapy. At 22-24 weeks into the TNT, follow-ups for response evaluation will be conducted, including colonoscopy and cross-sectional images such as CT, MR, and FDG-PET. The second 68Ga-FAPI PET will be performed within one month of these exams. Afterward, participants will either undergo surgery or have image follow-ups every 3 months. The participants will be followed up for up to 2 years after the second 68Ga-FAPI PET, and immunochemical staining with CD47, CD73, PD-L1, and FAP on the biopsy or surgical specimens will be performed in one batch to avoid batch-to-batch variation.

Study Overview

• Status: Recruiting
• Conditions: Rectal Neoplasms Malignant
• Intervention / Treatment: Radiation: Ga-68 FAPI

• Study Type: Observational
• Enrollment (Estimated): 99

Contacts and Locations

• Study Contact: Name: Shih-hsin Chen, MD PhD; Phone Number: 3565 886-3-3281200; Email: yevgenyc@cgmh.org.tw

Study Locations

• Taiwan
  • Taoyuan, Taiwan, 333
    • Recruiting
    • Chang Gung Memorial Hospital
    • Contact: Shih-hsin Chen, MD PhD; Phone Number: 3565 03-3281200; Email: yevgenyc@cgmh.org.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Those patient referred to the tertiary medical center for rectal cancer will be invited to enroll in the study.

Description

Inclusion Criteria:

1. Biopsy proven newly detected adenocarcinoma of the rectum
2. Clinical stage II-III rectal cancer
3. Aged at least 18 years. No upper age limit.
4. WHO/ECOG Performance Status 0-1
5. Eligible for total neoadjuvant therapy

Exclusion Criteria:

1. Distant metastases found on either CT, MR or FDG-PET
2. Prior anticancer therapy for colorectal cancer
3. Prior radiotherapy of the pelvic region
4. Other concurrent antineoplastic therapy
5. Major surgery within the last 4 weeks prior to inclusion
6. Subjects pregnant or breast feeding
7. Serious concurrent diseases not compatible with study entry, including active, uncontrolled infections, active, disseminated coagulation disorder, clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia within 6 months before enrolment)
8. Neurologic or psychiatric disorders including dementia, uncontrolled seizures, substance abuses, severe depression
9. Prior or concurrent malignancy within 3 years prior to enrolment (except non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1)
10. Allergic to contrast agents or to the main ingredients or excipients of the experimental radiopharmaceutical 68Ga FAPI, including acetate, ascorbic acid and normal saline
11. Those deemed unsuitable for participation in the trial by the investigators.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
observation; Ga-68 FAPI study before and during TNT	Radiation: Ga-68 FAPI; FAPI PET scans will be performed in addition to other staging/restaging work-up

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of FAPI SUV	To compare the FAPI uptake after TNT	before TNT & 22-24wk into TNT

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation of FAPI SUV	FAPI SUV will be correlated with (1) 2-year disease-free survival (DFS), (2) 2-year local regional recurrence (LRR), (3) 2-year total mesorectal excision (TME)-free survival, (4) 2-year overall survival (OS), (5) overall complete response (CR) rate, and (6) immune checkpoint protein expression including CD47, CD73, PD-L1, and FAP	2 years after recruitment

Collaborators and Investigators

• Sponsor: Chang Gung Memorial Hospital
• Collaborators: National Science and Technology Council
• Investigators: Principal Investigator: Shih-hsin Chen, MD PhD, Chang Gung Medical Foundation

Study record dates

Study Major Dates

• Study Start (Actual): March 8, 2024
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): July 31, 2028

Study Registration Dates

• First Submitted: November 27, 2023
• First Submitted That Met QC Criteria: November 27, 2023
• First Posted (Actual): December 5, 2023

Study Record Updates

• Last Update Posted (Actual): August 7, 2024
• Last Update Submitted That Met QC Criteria: August 6, 2024
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Neoplasms; Rectal Neoplasms
• Other Study ID Numbers: 202202030A0C601

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IPD will only be shared with co-investigators listed in the IRB application to protect the participants' privacy.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No